Dr. Nadim Nasr

I have not had an issue with re-spacing. I have had the issue of having to re-scan and re-simulate for planning just to confer. And I think the longest we had was about a three-month gap, and it still looked very good. I mean, I think it was a little bit small. I compared it back to what we had seen before.

I have not had an issue with re-spacing. I have had the issue of having to re-scan and re-simulate for planning just to confer. And I think the longest we had was about a three-month gap, and it still looked very good. I mean, I think it was a little bit small. I compared it back to what we had seen before.

I think the spacing was a little bit less, but it wasn't so much as I would have considered re-spacing. I think they were perfectly fine proceeding with treatment. Luckily, though, they had good anatomy as well. And that was three months after original placing? Three months after placement, whereas usually we'll scan usually about two weeks after spacing.

I think the spacing was a little bit less, but it wasn't so much as I would have considered re-spacing. I think they were perfectly fine proceeding with treatment. Luckily, though, they had good anatomy as well. And that was three months after original placing? Three months after placement, whereas usually we'll scan usually about two weeks after spacing.

I think the spacing was a little bit less, but it wasn't so much as I would have considered re-spacing. I think they were perfectly fine proceeding with treatment. Luckily, though, they had good anatomy as well. And that was three months after original placing? Three months after placement, whereas usually we'll scan usually about two weeks after spacing.

This is a big reason why we're the ones that are putting a lot of these spacers and fiducials in and not the urologists that send them to us. A lot of the urology groups that we get patients from have standing stentors. They're their own practices, and I think they're very happy not dealing with it, honestly.

This is a big reason why we're the ones that are putting a lot of these spacers and fiducials in and not the urologists that send them to us. A lot of the urology groups that we get patients from have standing stentors. They're their own practices, and I think they're very happy not dealing with it, honestly.

This is a big reason why we're the ones that are putting a lot of these spacers and fiducials in and not the urologists that send them to us. A lot of the urology groups that we get patients from have standing stentors. They're their own practices, and I think they're very happy not dealing with it, honestly.

I mean, that's exactly what I tell them is, you know, the gel will dissolve. I think they will end up with a lot less perirectal scarring in that area. And, you know, I've gotten some feedback from the gastroenterologists that we work with, really just for my own curiosity as to what they're seeing on colonoscopies on some of these patients, you know, routine colonoscopies. And

I mean, that's exactly what I tell them is, you know, the gel will dissolve. I think they will end up with a lot less perirectal scarring in that area. And, you know, I've gotten some feedback from the gastroenterologists that we work with, really just for my own curiosity as to what they're seeing on colonoscopies on some of these patients, you know, routine colonoscopies. And

I mean, that's exactly what I tell them is, you know, the gel will dissolve. I think they will end up with a lot less perirectal scarring in that area. And, you know, I've gotten some feedback from the gastroenterologists that we work with, really just for my own curiosity as to what they're seeing on colonoscopies on some of these patients, you know, routine colonoscopies. And

They do tell me that they're seeing a lot less telangiectasias in that anterior rectal wall. They're seeing a lot less post-radiation changes. I mean, they're still there. I don't think it's going to go away. We're still getting a decent dose of that anterior rectal wall, but it's certainly not something that I think has long-term consequences.

They do tell me that they're seeing a lot less telangiectasias in that anterior rectal wall. They're seeing a lot less post-radiation changes. I mean, they're still there. I don't think it's going to go away. We're still getting a decent dose of that anterior rectal wall, but it's certainly not something that I think has long-term consequences.

They do tell me that they're seeing a lot less telangiectasias in that anterior rectal wall. They're seeing a lot less post-radiation changes. I mean, they're still there. I don't think it's going to go away. We're still getting a decent dose of that anterior rectal wall, but it's certainly not something that I think has long-term consequences.

When we first started doing the spacer back in, I think it was 2016, 2017, when it first came out, most of the data was on external beam and IMRT. And there was actually very little data on SBRT. So we had some residents rotating through that put together some of our data for us. And essentially what we did was we did a comparison of rectal dosimetry for CyberKnife between patients that...

When we first started doing the spacer back in, I think it was 2016, 2017, when it first came out, most of the data was on external beam and IMRT. And there was actually very little data on SBRT. So we had some residents rotating through that put together some of our data for us. And essentially what we did was we did a comparison of rectal dosimetry for CyberKnife between patients that...

When we first started doing the spacer back in, I think it was 2016, 2017, when it first came out, most of the data was on external beam and IMRT. And there was actually very little data on SBRT. So we had some residents rotating through that put together some of our data for us. And essentially what we did was we did a comparison of rectal dosimetry for CyberKnife between patients that...

had spacer versus ones who did not have spacer and we tried to match patients up based on prostate size which was the one factor that we we thought would equal things out and essentially what we saw was anywhere between a 50 to 70 percent decrease in dose to the interior rectal wall and specifically a lot of the higher dose points, not just sort of the average lower dose, but the higher doses.

had spacer versus ones who did not have spacer and we tried to match patients up based on prostate size which was the one factor that we we thought would equal things out and essentially what we saw was anywhere between a 50 to 70 percent decrease in dose to the interior rectal wall and specifically a lot of the higher dose points, not just sort of the average lower dose, but the higher doses.

had spacer versus ones who did not have spacer and we tried to match patients up based on prostate size which was the one factor that we we thought would equal things out and essentially what we saw was anywhere between a 50 to 70 percent decrease in dose to the interior rectal wall and specifically a lot of the higher dose points, not just sort of the average lower dose, but the higher doses.